Meanwhile, an aggressive subset of prostate cancer patients will become resistant to ADT therapies and develop therapy‐induced t‐NEPC,32 with unique features of AR loss and expression of neuroendocrine lineage markers. This evidence concerns the gene AR and prostate cancer.